HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>The results of National TCM VBP were released, with average price reduction of 49.36%, involving multiple large varieties with sales over RMB1 billion and exclusive products from many listed companies.</li>
<li>CDE will move closer to the FDA's standard for approving new drugs. So, pharmaceutical companies need to update clinical strategies timely according to the situation, otherwise unexpected events may occur.</li>
<li>We analyzed some key points about <a href="https://www.smartkarma.com/entities/hua-medicine" target="_blank" data-smartkarma-citation="entities:27410:1" rel="noopener">Hua Medicine Ltd (2552 HK)</a>. We think its core drug Dorzagliatin still has many uncertainties that are worth investors' attention.</li>
</ul>


The results of National TCM VBP were released, with average price reduction of 49.36%, involving multiple large varieties with sales over RMB1 billion and exclusive products from many listed companies.
CDE will move closer to the FDA's standard for approving new drugs. So, pharmaceutical companies need to update clinical strategies timely according to the situation, otherwise unexpected events may occur.
We analyzed some key points about Hua Medicine Ltd (2552 HK). We think its core drug Dorzagliatin still has many uncertainties that are worth investors' attention.


China Healthcare Weekly (Jun.23) - National TCM VBP Results, CDE Changes Game Rule, Hua Medicine

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine for holding position as of January 13th.</li>
<li>We estimate the weekly inflows to be US$6,510.6 million, led by financials, consumer staples, information technology sectors, and offset by energy, real estate.</li>
<li>We highlight flows for CATL, Ping An Insurance, Moutai, Wuliangye, Longi Green Energy Technology, Jiangsu Hengrui Medicine.</li>
</ul>


We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine for holding position as of January 13th.
We estimate the weekly inflows to be US$6,510.6 million, led by financials, consumer staples, information technology sectors, and offset by energy, real estate.
We highlight flows for CATL, Ping An Insurance, Moutai, Wuliangye, Longi Green Energy Technology, Jiangsu Hengrui Medicine.


Northbound Flows (Jan 13th): 1Y High Weekly Inflows

<ul>
<li>We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine for holding position as of December 30th.</li>
<li>We estimate the weekly inflows to be US$457.7 million, led by financials, consumer staples, utilities sectors, and offset by industrials, materials.</li>
<li>We highlight flows for Ping An Insurance, Yibin Wuliangye, CATL. </li>
</ul>


We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine for holding position as of December 30th.
We estimate the weekly inflows to be US$457.7 million, led by financials, consumer staples, utilities sectors, and offset by industrials, materials.
We highlight flows for Ping An Insurance, Yibin Wuliangye, CATL. 


Northbound Flows (Dec 30th): Ping An, Wuliangye, CATL

Equity Capital Markets

Shanghai Ark Biopharmaceutical / Equity Capital Markets

<p>In the era of excessive competition of anti-tumor drugs, many enterprises began to make layout in other fields such as ophthalmologic drugs, respiratory drugs, dermatologic drugs, antiviral drugs and so on. On June 29<sup>th</sup>, 2021, <a href="https://www.smartkarma.com/entities/shanghai-ark-biopharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:33766:1" rel="noopener">Shanghai Ark Biopharmaceutical (SAB HK)</a> submitted its prospectus to the HKEX and officially started its IPO process. Ark is an innovative biopharmaceutical company focused on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. This insight mainly analyzed the important product candidates in the pipeline and related concerns.</p>

In the era of excessive competition of anti-tumor drugs, many enterprises began to make layout in other fields such as ophthalmologic drugs, respiratory drugs, dermatologic drugs, antiviral drugs and so on. On June 29th, 2021, Shanghai Ark Biopharmaceutical (SAB HK) submitted its prospectus to the HKEX and officially started its IPO process. Ark is an innovative biopharmaceutical company focused on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. This insight mainly analyzed the important product candidates in the pipeline and related concerns.

Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns

China

Guangdong Zhongsheng Pharmaceutical Co Ltd manufactures pharmaceuticals from traditional Chinese medicinal ingredients.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Guangdong Zhongsheng Pha A (002317 CH)

China Healthcare Weekly (Jun.23) - National TCM VBP Results, CDE Changes Game Rule, Hua Medicine

Results of National TCM VBP were released, involving some big varieties. CDE changes game rule on drug approva. Companies has to change clinical...

Xinyao (Criss) Wang

Northbound Flows (Jan 13th): 1Y High Weekly Inflows

We analyzed northbound Shanghai/Shenzhen connect flows in the past week and highlight flows for CATL, Ping An Insurance, Moutai, Wuliangye, Longi...

Ke Yan, CFA, FRM

Northbound Flows (Dec 30th): Ping An, Wuliangye, CATL

We analyzed the Shanghai/Shenzhen Connect Scheme for last week and highlight flows for Ping An Insurance, Wuliangye, CATL.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

China Healthcare Weekly (Jun.23) - National TCM VBP Results, CDE Changes Game Rule, Hua Medicine

Results of National TCM VBP were released, involving some big varieties. CDE changes game rule on drug approva. Companies has to change clinical...

Xinyao (Criss) Wang

Northbound Flows (Jan 13th): 1Y High Weekly Inflows

We analyzed northbound Shanghai/Shenzhen connect flows in the past week and highlight flows for CATL, Ping An Insurance, Moutai, Wuliangye, Longi...

Ke Yan, CFA, FRM

Northbound Flows (Dec 30th): Ping An, Wuliangye, CATL

We analyzed the Shanghai/Shenzhen Connect Scheme for last week and highlight flows for Ping An Insurance, Wuliangye, CATL.

Ke Yan, CFA, FRM

Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns

The article mainly analyzed Ark Biopharmaceutical in terms of the important product candidates AK0529 (ziresovir) and AK3280 that entered the...

Xinyao (Criss) Wang